Abstract Objective To investigate the efficacy and safety of lamotrigine monotherapy in children with epilepsy via a systematic review. Methods PubMed, Cochrane, CNKI, VIP, CBM, Wanfang Data were searched for randomized controlled trials (RCTs) of lamotrigine monotherapy in children with epilepsy. Literature screening, data extraction, and quality assessment were performed according to the method recommended by Cochrane Collaboration. RevMan 5.2 software was used to conduct the Meta analysis. Results A total of 9 RCTs involving 1 016 participants were included. Lamotrigine yielded a significantly lower complete control rate of seizure than ethosuximide, but the complete control rate of seizure showed no significant differences between lamotrigine and carbamazepine/sodium valproate. Patients treated with lamotrigine had a significantly lower incidence rate of adverse events than those treated with carbamazepine, but the incidence rate of adverse events showed no significant differences between patients treated with lamotrigine and sodium valproate/carbamazepine. The drop-out rate showed no significant differences between the three treatment groups. Conclusions Lamotrigine is an ideal alternative drug for children who do not respond to traditional antiepileptic medication or experience significant adverse reactions; however, more high-quality RCTs with a large sample size and a long follow-up time are needed to confirm these conclusions.
Sitges M, Guameros A, Nekrassov V, et al. Effects of carbamazeping, phenytion, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpoceting on the presynaptic Ca2+ channel-mediated release of [3H] glutamate: Comparison with the Na+ channel-mediated release[J]. Neuropharmacology, 2007, 53(7): 854-862.
[7]
Stefani A, Spadoni F, SiniscalchiA, et a1. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications[J]. Eur J Pharmacol, 2006, 307(1): 113-116.
Biton V, Levisohn P, Hoyler S, et al. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial[J]. Journals of Child Neurology, 2003, 18(2): 133-139.
[18]
Coppola G, AuricchioG, Federico R, et al. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallelgroup study[J]. Epilepsia, 2004, 45(9): 1049-1053.
[19]
Eun SH, Eun BL, Lee JS. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy[J]. Brain & Development, 2012, 34(10): 818-823.
[20]
Nieto-Barrera M, Brozmanova M, Capovilla G. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy[J]. Epilepsy Research, 2001, 46(2): 145-155.
[21]
Glause TA, Cnaan A, ShinnarS. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: Initial monotherapy outcomes at 12 months[J]. Epilepsia, 2013, 54(1): 141-155.
[22]
Commission on antiepileptic drugs. Considerations on designing clinical trials toevaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy[J]. Epilepsia, 1998: 39(7): 799-803.
